ADMA BIOLOGICS, INC. Marketing and Advertising Expense
ADMA BIOLOGICS, INC. (ADMA) reported Marketing and Advertising Expense of $3.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingAndAdvertisingExpense · last filed 2026-02-25
- ADMA BIOLOGICS, INC. marketing and advertising expense for fiscal 2025 was $3.10M, a 14.81% increase from fiscal 2024.
- ADMA BIOLOGICS, INC. marketing and advertising expense for fiscal 2024 was $2.70M, a 18.18% decline from fiscal 2023.
- ADMA BIOLOGICS, INC. marketing and advertising expense for fiscal 2023 was $3.30M, a 50.00% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. marketing and advertising expense for fiscal 2022 was $2.20M, a 0.00% change from fiscal 2021.
| Period end | Marketing and Advertising Expense 12 month | Marketing and Advertising Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $3.10M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $2.70M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $3.30M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $2.20M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $2.20M 10-K · filed 2025-03-18 | $1.40M 10-K · filed 2022-03-24 |
| 2020-12-31 | $1.10M 10-K · filed 2022-03-24 | |
| 2019-12-31 | $1.00M 10-K · filed 2021-03-25 | |
| 2018-12-31 | $800.00K 10-K · filed 2020-03-13 | |
| 2017-12-31 | $600.00K 10-K · filed 2019-03-13 | |
| 2016-12-31 | $200.00K 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |